Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

…, C Leonardi, A Wang, D Lalla, M Woolley, A Jahreis… - The Lancet, 2006 - thelancet.com
Background Psoriasis has substantial psychological and emotional effects. We assessed the
effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue …

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks

…, M Dunn, CF Chiou, V Patel, A Jahreis - British Journal of …, 2007 - academic.oup.com
5 Fonder MA, Cummins DL, Ehst BD et al. Adalimumab therapy for recalcitrant pyoderma
gangrenosum. J Burns Wounds 2006; 5: e8. 6 Heffernan MP, Anadkat MJ, Smith DI …

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

…, B Wagner, J Siegel, A Jahreis… - The Lancet …, 2020 - thelancet.com
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …

[HTML][HTML] Etanercept treatment for children and adolescents with plaque psoriasis

…, V Patel, K Creamer, A Jahreis - … England Journal of …, 2008 - Mass Medical Soc
Background Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen
disease severity in adult patients with psoriasis. We assessed the efficacy and safety of …

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

D Khanna, CP Denton, A Jahreis, JM van Laar… - The lancet, 2016 - thelancet.com
Background Systemic sclerosis is a rare disabling autoimmune disease with few treatment
options. The efficacy and safety of tocilizumab, an interleukin 6 receptor-α inhibitor, was …

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

…, AB Gottlieb, M Dunn, A Jahreis - Archives of …, 2007 - jamanetwork.com
Objective To evaluate the safety and efficacy of long-term treatment of psoriasis with
etanercept, 50 mg twice weekly. Design, Setting, and Patients A phase 3, randomized …

[HTML][HTML] Integrated safety in tocilizumab clinical trials

MH Schiff, JM Kremer, A Jahreis, E Vernon… - Arthritis research & …, 2011 - Springer
Introduction The efficacy and safety of tocilizumab in patients with rheumatoid arthritis have
been evaluated in a comprehensive phase 3 program. Patients from these randomized trials …

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

…, L Ye, Y Guo, C Tasset, JS Sundy, A Jahreis… - Annals of the …, 2021 - ard.bmj.com
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

…, H Spotswood, L Burke, J Siegel, A Jahreis… - Annals of the …, 2018 - ard.bmj.com
Objectives Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis
(SSc) in a phase II study. Methods Patients with SSc were treated for 48 weeks in an open …

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior …

…, Z Yin, Y Guo, C Tasset, JS Sundy, A Jahreis… - Annals of the …, 2021 - ard.bmj.com
Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in
patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) …